Codon Devices Opens European Headquarters
News Oct 03, 2007
Codon Devices, Inc., the Constructive Biology Company™, today announced its expansion into Europe with the formation of Codon Devices U.K. Ltd., and the appointment of Michael Dyson, PhD, to the newly-created position of European Managing Director.
“We are excited to open our new European headquarters as a major step in our global expansion plans,” said John P. Danner, President and Chief Executive Officer of Codon Devices.
“As we industrialize synthetic biology and drive a new paradigm in research called Constructive Biology™, we are experiencing rapid adoption of our advanced gene synthesis and protein engineering offerings. The interest from the European marketplace is tremendous and we are looking forward to serving these customers more effectively through this new base of operations.”
Michael Dyson will lead Codon Devices U.K., Ltd., reporting to Michael J. Fitzpatrick, Vice President, Global Sales, Codon Devices, Inc. Dr. Dyson has more than 20 years of experience leading European customer service and sales organizations in the life sciences industry. Prior to joining Codon Devices, Dr. Dyson was Managing Director for Sequenom, GmbH and Director, European Sales and Marketing for MicroCal, LLC.
“Mike brings exceptional leadership capability and in-depth knowledge of the European market,” said Michael Fitzpatrick. “His proven track record of building successful operations to drive growth and customer satisfaction make him a valuable addition to our team.”
“Codon Devices has established strong relationships with many European pharmaceutical, biotechnology and agribusiness-focused companies, as well as renowned centers of academic research,” said Michael Dyson. “I am excited to build upon Codon’s strong position in the market through this new headquarters and the rapid installation of direct sales operations throughout Europe.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.